From Academic Foundations to Applied Intelligence: Dr. Murali Addepalli’s Journey in Advancing Biologics Toward Patient CareWork across NIH research, industry biologics programs, and emerging AI applications in drug discovery.
Most researchers dream of discovering breakthrough therapies. Dr. Murali Addepalli set himself a different, more audacious goal: actually, getting one to patients. Not publishing elegant papers about potential therapeutics that remain trapped in academic journals. Not generating promising preclinical data that never survives clinical translation. Actually, contributing meaningfully to creating a medicine that reaches someone who needs it—”a lifetime achievement,” as he describes it with characteristic directness.
This clarity of purpose has shaped every pivotal decision across his career: transitioning from NIH postdoctoral research into industry when he recognised that translating scientific ideas into real medicines required resources and scale that academia couldn’t provide; shifting focus from siRNA therapeutics to biologics when delivery limitations threatened to constrain broader therapeutic application; co-founding entrepreneurial ventures when conventional R&D structures proved too rigid to absorb rapidly advancing technologies; and now building SANSHI Bio Solutions around the principle of “Better Health through Amplified Intelligence”—combining deep human domain expertise with AI-driven discovery to compress development timelines whilst improving success probability.
As Co-founder and Chief Scientific Officer, Dr. Addepalli architects end-to-end R&D programmes spanning oncology and autoimmune indications, wielding sophisticated platforms including monoclonal antibodies, therapeutic proteins, and immune-modulating modalities. His technical repertoire extends from systems pharmacology enabling polypharmacological therapeutic design to regulatory expertise navigating IND filings and clinical development pathways. This breadth reflects deliberate cultivation of capabilities required to move molecules from concept through clinical validation—the complete journey necessary to achieve his foundational goal of developing therapies that reach patients.
His career trajectory provides unique vantage on biologics development’s evolution. At Reliance Life Sciences as Scientist, he developed siRNA-based therapeutic modalities demonstrating strong proof-of-concept in animal models whilst confronting the technological limitations constraining siRNA’s broader application. At Nektar Therapeutics, he worked extensively on cytokine pharmacology—IL-2, IL-15, IL-7—leveraging Nektar’s platform technology that fundamentally altered biologics’ pharmacokinetic and pharmacological behaviour. Several programmes he contributed to advanced into clinical trials, validating the platform’s translational strength whilst providing firsthand experience navigating late-stage development’s complexities.
This journey through siRNA challenges, cytokine research, checkpoint antibody combinations, and now AI-enabled discovery positions Dr. Addepalli to assess both where immune therapeutics have evolved and where they’re heading. His entrepreneurial ventures—first Lextro Bio Solutions, now SANSHI—reflect conviction that conventional R&D structures cannot match technological innovation’s accelerating pace, and that focused startups integrating new technologies early whilst aligning discovery tightly with development requirements can create capital-efficient pipelines delivering real clinical and commercial outcomes.
Ahead of his presentation at the Bioxyra Summit, we explored the pivotal transitions shaping his career, the shifts he’s witnessed in immune therapeutics’ scientific foundations and execution models, and his perspective on what India’s biologics sector requires—beyond funding—to accelerate from manufacturing strength toward innovation leadership.
The Academic-to-Industry Bridge: When Translation Becomes the Mission
The transition from academic research to industry involves more than changing employers—it requires fundamental reorientation around what constitutes meaningful achievement, how success is measured, and what timeline governs decision-making. Dr. Addepalli’s transition, whilst earlier than many researchers’, established patterns that would define his subsequent career.
How did your journey from PhD research into the biologics industry actually begin? What prompted that initial move?
“My transition from academia to industry began during my postdoctoral training at the NIH in Bethesda, USA, where I was introduced to siRNA technologies, which at the time were emerging as a powerful new modality in drug discovery and development. What fascinated me most was their ability to modulate so-called ‘undruggable’ targets, something that conventional small-molecule approaches struggled to achieve.
From early in my career, I had a clear personal goal: to develop—or meaningfully contribute to—the creation of at least one therapeutic that could reach patients in need. I consider that, in itself, a lifetime achievement. To realise this ambition, I felt that the industry environment offered the scale, resources, and translational focus necessary to convert scientific ideas into real medicines.
During this period, I joined Reliance Life Sciences as a Scientist, marking my formal transition into industry. Over the next three to four years, I worked on developing multiple siRNA-based therapeutic modalities, several of which demonstrated strong proof-of-concept in animal models. However, as the programmes advanced, we encountered the scientific and technological limitations of siRNA delivery, which at that time significantly constrained its broader therapeutic application.
These challenges led me to reassess the therapeutic landscape. It became increasingly clear that biologic therapies—particularly protein-based and immune-modulating biologics—offered improved safety profiles and greater translational potential compared to many small-molecule approaches. Driven by my continued focus on addressing unmet medical needs, this realisation naturally guided my journey toward biologics and immune therapeutics, culminating in my decision to join Nektar Therapeutics in Hyderabad where the profile of the job offered is what I desired.”
The goal—”develop at least one therapeutic that could reach patients in need”—captures ambition grounded in realistic assessment of what constitutes meaningful achievement. Many researchers pursue multiple publications, prestigious grants, or academic appointments; Dr. Addepalli defined success differently: actual therapeutic impact. This clarity enabled decisive transitions when pathways proved unlikely to reach that destination.
The siRNA experience proves particularly instructive. Demonstrating “strong proof-of-concept in animal models” represents significant scientific achievement—publishable results, validated technology, promising therapeutic potential. Yet Dr. Addepalli recognised that delivery limitations threatened preventing siRNA therapeutics from reaching patients at scale, rendering scientific elegance insufficient. The willingness to reassess and pivot—abandoning promising work when fundamental constraints emerge—distinguishes leaders who ultimately deliver therapies from those who pursue scientifically interesting projects regardless of translational viability.
The shift toward biologics reflects strategic thinking beyond immediate technical challenges toward broader therapeutic landscape assessment. Protein-based and immune-modulating biologics offered “improved safety profiles and greater translational potential”—characteristics directly supporting the fundamental goal of creating therapies actually reaching patients. This strategic clarity about ultimate objectives enables tactical flexibility about specific modalities, technologies, and approaches.
The shift to biotech drug discovery—when did that interest actually take root for you?
“My interest in the biotech drug discovery industry actually took root during my Master’s studies at the University of Hyderabad. It was an intellectually vibrant environment, with exceptionally talented professors and seniors who consistently inspired us—not only through formal lectures, but also through informal discussions about real-world scientific impact.
I am grateful to faculty members including Prof. Reddanna Pallu, Prof. C. H. R. K. Murthy, and Dr. Bhaskar Reddy, who significantly influenced my thinking. Through their teaching and conversations, they demonstrated how biotechnology-driven drug discovery can offer solutions to unmet medical needs, directly translating fundamental science into patient benefit.
Those interactions helped crystallise my long-term goal: to pursue a career where scientific rigour is coupled with meaningful therapeutic impact. That early exposure during my Master’s training ultimately set the direction for my journey into biotech drug discovery and development.”
The attribution to specific faculty members reflects how mentorship shapes career trajectories in ways that formal curriculum cannot. Professors who merely deliver lectures transmit information; those who engage students in “informal discussions about real-world scientific impact” shape how students conceptualise their potential contributions and what constitutes worthwhile work. The emphasis on “directly translating fundamental science into patient benefit” established framework that would guide Dr. Addepalli’s subsequent decisions.
Could you share a significant challenge you faced early in your industry career and how you navigated through it?
“The biggest challenge early on was shifting my mindset from academic science to industry science. In academia, you’re rewarded for depth and discovery; in industry, you’re accountable for outcomes, timelines, and regulatory rigour.
I was fortunate that during my Master’s studies, and later during my PhD in Japan, my supervisor, Prof. Yuji Fujita, trained me to think about translation and real-world impact, which helped ease the transition. Once in industry, I consciously learned to frame every experiment around a clear objective—how does this move a programme closer to a therapy?
That shift was a turning point. It taught me to balance scientific curiosity with decision-making, accountability, and team alignment—a mindset that’s been central to my leadership approach ever since.”
The distinction—academia rewards “depth and discovery” whilst industry demands “outcomes, timelines, and regulatory rigour”—captures fundamentally different value systems. Academic careers advance through publications demonstrating novelty and mechanistic insight; commercial success requires delivering defined products meeting regulatory standards within competitive timeframes. Neither approach is inherently superior, but conflating them causes problems when academic-trained scientists enter industry expecting depth and discovery to receive equivalent recognition.
The conscious reframing—”how does this move a programme closer to a therapy?”—represents the essential mindset shift. Every experiment, every optimisation, every analytical method development must justify itself against this ultimate criterion.
Professional Journey in Immune Therapeutics Dr. Addepalli’s work in immune therapeutics has taken place during a period of significant change — from early cytokine research and checkpoint antibody combinations to more recent AI-supported approaches aimed at improving discovery efficiency. His experience across these phases has offered practical insight into both the scientific progress and the evolving strategic considerations in the field.
How has your work on immune therapeutics evolved over the years? What shifts have you seen both in the science and in your approach?
“In my career at Nektar Therapeutics, I worked extensively on the pharmacology of multiple cytokines, including IL-2, IL-15 and IL-7. Nektar’s technology platform is particularly noteworthy, as it fundamentally altered the PK and pharmacological behaviour of biologics—especially cytokines—by modulating how they interact with their receptors. Several of these programmes have since advanced into Phase II and Phase III clinical trials, underscoring the translational strength of the platform.
Concurrently, an improved understanding of disease biology has driven the adoption of combination-therapy strategies. Earlier, at Reliance Life Sciences, I worked on such approaches using siRNA-based combinations, and later at Nektar, on combinations involving bempegaldesleukin and nivolumab. These studies were instrumental in establishing partnerships with checkpoint antibody companies, as the underlying science consistently demonstrated synergistic responses in vitro and in animal models.
More recently, advanced 3D spheroid and organoid models derived from primary tumours have shown superior predictive value, as they incorporate multiple components of human origin. These systems enhance reproducibility whilst significantly reducing reliance on animal models and associated suffering, aligning both scientific and ethical priorities.
We are now in a post-checkpoint antibody and CAR-T phase, where bi- and tri-specific antibodies with targeted delivery are becoming increasingly common in discovery research. Multiple regulatory approvals continue to fuel momentum in immune therapeutics. In parallel, bispecific CARs and in vivo CAR approaches are rapidly advancing. Notably, several in vivo CAR programmes have already entered clinical development, demonstrating promising activity in solid tumours. These therapies may have the potential to become more scalable and cost-effective than current ex vivo CAR-T platforms and may ultimately take centre stage in the treatment of cancer and autoimmune diseases.
At the same time, drug discovery and development timelines are shrinking dramatically due to the adoption of AI-driven tools. We can now generate de novo antibodies and proteins, with recent publications reporting binder success rates of ~39%. Processes that traditionally required 5-6 years can now be completed in few weeks, reflecting the pace at which the field is evolving. This transformation extends beyond immune therapeutics and marks a broader golden age of drug discovery, where conventional approaches are increasingly replaced by modern, data-driven technologies.
At SANSHI, our objective is to develop better therapeutics through amplified intelligence—the seamless integration of human insight with artificial intelligence. AI does not replace scientific judgement; rather, it multiplies the speed and depth of human thinking, enabling more informed, faster, and more impactful therapeutic development.”
The Nektar platform’s impact—”fundamentally altered the PK and pharmacological behaviour of biologics”—illustrates how enabling technologies can transform entire therapeutic classes. Cytokines’ powerful immune-modulating effects were well-known, but their clinical utility was constrained by unfavourable pharmacokinetics and receptor interactions causing toxicity or insufficient duration. Platform technologies addressing these limitations unlocked cytokines’ therapeutic potential, enabling programmes advancing into late-stage clinical development.
The shift toward combination therapies reflects maturation in understanding that complex diseases like cancer rarely succumb to single-agent interventions. Checkpoint antibodies revolutionised oncology but benefit only patient subsets; combining with cytokines or other immune modulators expands response rates and durability. The partnerships with checkpoint antibody companies demonstrate how scientific synergy demonstrated “in vitro and in animal models” translates into commercial collaborations where companies possessing complementary assets combine them to create superior therapies.
The observation about 3D spheroid and organoid models addresses persistent challenge in drug development: animal models’ poor predictive value for human responses. Models incorporating “multiple components of human origin” better recapitulate actual tumour biology, improving prediction whilst reducing animal suffering—a dual benefit aligning scientific and ethical imperatives.
The characterisation as “post-checkpoint antibody and CAR-T era” signals field maturation beyond initial breakthroughs toward next-generation approaches. Bi- and tri-specific antibodies offer precision that monoclonal antibodies cannot achieve; in vivo CAR approaches promise to democratise cell therapy by eliminating expensive, patient-specific ex vivo manufacturing. These advances represent evolution from pioneering therapies benefiting small patient populations toward scalable platforms potentially reaching broader populations.
The AI transformation—”processes that traditionally required 5-6 years can now be completed in few weeks”—represents perhaps the most dramatic shift. This isn’t incremental improvement but order-of-magnitude acceleration fundamentally altering what’s possible within realistic development timelines and budgets.
The framing—”amplified intelligence” rather than artificial intelligence replacing human judgement—captures appropriate perspective. AI tools excel at pattern recognition, optimisation within defined parameters, and systematic exploration of vast possibility spaces. They don’t replace scientific insight about which targets matter, what therapeutic hypotheses merit testing, or how to interpret unexpected results. The combination—human insight identifying promising directions, AI accelerating execution—proves more powerful than either alone.
What inspired you to co-found SANSHI Bio Solutions? What gap or opportunity did you see that made entrepreneurship the right path?
At SANSHI Bio Solutions, the strategic rationale has been consistent. My focus has always been on translating advanced science into meaningful, scalable therapeutics and platforms that address clear unmet medical needs.
Having worked across large multinational pharma as well as smaller biotech organisations, I observed a recurring gap: scientific innovation was advancing faster than conventional R&D structures could absorb and execute. Emerging technologies—whether novel biologics, immune modalities, or AI-enabled discovery—often struggled to move efficiently through rigid pipelines.
Entrepreneurship offered a solution to this inefficiency. A focused startup can integrate new technologies early, make faster decisions, and align discovery tightly with downstream development and partnering requirements. That was the opportunity behind Lextro—and it is now more fully realised at SANSHI Bio Solutions.
SANSHI is built around the principle of ‘Better Health through Amplified Intelligence’—combining deep human domain expertise with AI-driven discovery to compress timelines, improve success probability, and create capital-efficient pipelines. For investors, the opportunity lies in faster value inflection, multiple partnering options, and scalable platform-driven growth, rather than a single-asset bet.
In short, entrepreneurship was the right path because it allowed us to match the pace of technological innovation with an execution model capable of delivering real clinical and commercial outcomes.”
The diagnosis—”scientific innovation was advancing faster than conventional R&D structures could absorb and execute”—identifies structural problem affecting large pharmaceutical organisations. Established companies optimise around existing technologies and proven approaches; integrating fundamentally new modalities requires changing processes, retraining personnel, and accepting risks that conservative organisations resist. This creates opportunity for startups unburdened by legacy approaches and capable of building processes optimised for new technologies from inception.
The emphasis on “capital-efficient pipelines” and “faster value inflection” addresses investor perspective often missing from purely scientific narratives. Venture capital funding biotechnology seeks returns through eventual exits—acquisitions by larger companies, partnerships generating milestone payments, or public market liquidity. Achieving these outcomes requires not just scientific success but strategic positioning enabling partnerships, clear value inflection points de-risking programmes, and capital efficiency ensuring funding lasts until value-creation milestones are reached.
The platform versus single-asset framing—”scalable platform-driven growth, rather than a single-asset bet”—speaks to risk management considerations. Single-asset biotechs face binary outcomes: the drug succeeds and investors profit handsomely, or it fails and investments vanish. Platform companies can weather individual programme failures because the infrastructure enabling discovery remains valuable for subsequent candidates, creating portfolio approach improving overall success probability.
India’s Biologics Future: Beyond Funding to Infrastructure and Execution
Dr. Addepalli’s experience spanning multinational pharma, Indian biotech, and entrepreneurial ventures positions him uniquely to assess what India’s biologics sector requires to accelerate beyond current capabilities. His perspective extends beyond conventional emphasis on funding toward infrastructure, regulatory frameworks, and execution capabilities.
How do you think the India-EU Free Trade Agreement might impact India’s biologics sector? What opportunities or challenges do you anticipate?
“Overall, I see the India-EU Free Trade Agreement as very positive news for both patients and the life-sciences ecosystem, particularly for biologics and advanced therapies. Whilst I wouldn’t claim to be a trade-policy expert, the broad direction is clearly supportive of growth and collaboration.
On the opportunity side, reduced or eliminated tariffs on biologics and related exports to EU member states could significantly improve the global competitiveness of Indian companies. This has the potential to create momentum similar to what India experienced in generic pharmaceuticals, but now extended to complex biologics and biosimilars. Importantly, the absence of WTO TRIPS-plus obligations preserves India’s flexibility around IP and manufacturing, which is critical for innovation and affordability.
The agreement is also likely to unlock stronger EU funding flows, co-development programmes, and academic-industry collaborations, particularly benefiting startups and mid-sized biotech companies. Improved access to high-end laboratory equipment, reagents, and specialised technologies from Europe could further strengthen India’s R&D capabilities and shorten development timelines.
That said, there are challenges to anticipate. Greater access to EU markets will also mean higher expectations around regulatory compliance, quality systems, and data integrity, especially under EMA standards. Companies that invest early in these capabilities will benefit most, whilst others may face a learning curve.
In summary, the FTA presents a structural opportunity for India’s biologics sector to move up the value chain—from cost-efficient manufacturing to innovation-led discovery and development. Those who align science, quality, and partnerships effectively stand to create significant long-term value.”
The parallel to generic pharmaceuticals—”momentum similar to what India experienced in generic pharmaceuticals, but now extended to complex biologics”—captures both opportunity and challenge. India’s generic pharmaceutical success derived from cost-competitive manufacturing and regulatory frameworks enabling rapid market entry post-patent expiry. Biologics and biosimilars require substantially more sophisticated capabilities: complex manufacturing, extensive analytical characterisation, potentially required clinical studies. Companies successfully making this transition can capture higher-value markets, but the technical and regulatory bar proves substantially higher.
The preservation of “India’s flexibility around IP and manufacturing” addresses concern that trade agreements might constrain India’s ability to manufacture medicines for domestic needs or export to developing markets. Maintaining this flexibility proves essential for India’s dual role as both innovation centre and affordable medicine provider for resource-constrained populations.
The emphasis on “regulatory compliance, quality systems, and data integrity” as challenges alongside opportunities reflects realistic assessment. Trade agreements open markets but don’t automatically confer competitiveness; Indian companies must meet stringent European standards to actually capture opportunities. Those investing proactively in these capabilities position themselves advantageously; those treating compliance as afterthought face difficulties.
We see that the biologics industry of India is progressing rapidly. Do you really think that funding is the real obstacle this industry is currently going through? What should government do regarding these things or what other options are available?
“Of course, funding is always a challenge for the biotech industry. Currently, there are a lot of schemes out there. Most of these schemes have limited cash to be given to the startup organisations or even for the larger organisations where they would be requiring to conduct clinical trials and so on. So, maybe it’s more of a little bit of liberalisation in funding and removing some of the stringent or stricter rules and regulations may help the funding scenario for the biologics as a whole.”
In the EU trade context, will more trade and government initiatives help this industry? What other incentives should government take?
“Of course, it does. Like I said, establishing more technology centres where accessibility for the high-end equipment and manufacturing facilities if it is provided at multiple locations, not just in one or two locations. And their numbers and their scale, if it gets increased, which can help for the startups or for the small or medium industries to go and utilise on the basis of no-service or free kind of something. That will help us better.”
The emphasis on “more technology centres” with “accessibility for high-end equipment and manufacturing facilities… at multiple locations” addresses infrastructure gap that funding alone cannot solve. Early-stage companies cannot justify purchasing expensive equipment—mass spectrometers, high-resolution imaging systems, specialised bioreactors—that may be needed only periodically. Shared facilities amortise equipment costs across multiple users, enabling access that individual companies couldn’t afford whilst ensuring equipment utilisation justifies investment.
The geographic distribution consideration—”multiple locations, not just in one or two locations”—acknowledges that concentrating resources in major metros like Bangalore or Hyderabad disadvantages companies or researchers located elsewhere. Distributed infrastructure enables broader participation whilst building regional capabilities that strengthen ecosystem overall.
Do you think in this funding obstacle, the startups are more struggling?
“I don’t say it’s struggling. It requires better investments. That’s what I would say. For the rapid progress.”
The reframing from “struggling” to “requires better investments” reflects distinction between fundamental viability challenges and growth capital constraints. Struggling companies face existential threats from flawed business models or insufficient capabilities; companies requiring “better investments” possess viable approaches but need capital to accelerate execution. This optimistic framing suggests India’s biologics sector’s fundamental trajectory is sound but that appropriate capital could dramatically accelerate progress.
What are your expectations from the Bioxyra Summit? Will it help the biologics industry or biologics professionals more?
“Well, probably more. We are inviting a large number of vaccine professionals, industries, as well as I do see some government officials to this meeting. And during this thing, I think there are significant brainstorm sessions and presentations out there, which will definitely help both the government as well as the private industries to forge better ties and to evolve consensus to improve both the funding as well as the infrastructure capabilities.”
The emphasis on “forge better ties and evolve consensus” captures summits’ crucial but often underappreciated function: creating shared understanding between stakeholders who typically interact minimally. For Dr. Addepalli, the summit represents opportunity to share SANSHI’s journey whilst learning from others tackling similar challenges through different approaches. “We’re pioneering AI-enabled discovery in India, but we’re not the only ones innovating in how biologics development gets executed. Others are advancing continuous manufacturing, developing novel delivery technologies, or creating new business models for accessing global markets. Every approach offers insights potentially applicable to our work.”
The broader vision involves India’s biologics sector evolving from capable executor of established approaches toward genuine innovator setting new paradigms. “We’ve demonstrated we can manufacture high-quality biologics cost-effectively. The next frontier involves developing novel therapeutics, pioneering new technologies, and creating execution models that global industry adopts because they’re demonstrably superior—not just cheaper.”
This transformation requires more than individual company successes—it demands ecosystem evolution where infrastructure supports innovation, funding mechanisms match biologics’ unique requirements, regulatory frameworks enable rather than obstruct progress, and talent development produces professionals possessing sophisticated capabilities that innovation demands. “No single company, however successful, creates this ecosystem alone. It requires coordinated effort across government, industry, academia, and investors—precisely the constituencies Bioxyra brings together.”
Dr. Addepalli’s participation brings perspective spanning academic training emphasising translational impact, industry experience across siRNA challenges and cytokine research successes, entrepreneurial ventures building capital-efficient pipelines leveraging AI, and current leadership architecting end-to-end programmes from discovery through clinical development. This breadth informs nuanced understanding of what’s required to actually deliver therapies reaching patients—the goal that’s guided every career decision.
The Bioxyra Summit, by convening leaders who’ve driven India’s biologics progress alongside government officials shaping policy frameworks and investors providing capital, creates essential platform for the alignment, consensus-building, and collaborative problem-solving that transforms individual successes into sector-wide acceleration. Dr. Addepalli’s emphasis on “Better Health through Amplified Intelligence” captures both the technological frontier and the collaborative imperative—leveraging AI to multiply human insight whilst ensuring that innovation actually reaches the patients who inspired his career journey from its inception.
Dr. Murali Addepalli will be a featured speaker at the Bioxyra Summit, where he will share insights from his journey across siRNA research, cytokine research, and AI-enabled discovery, whilst discussing what India’s biologics sector requires beyond funding to accelerate toward innovation leadership. His perspectives on immune therapeutics evolution, entrepreneurial execution models, and infrastructure priorities will inform attendees navigating India’s biologics transformation.
Pingback: News – biofaba